Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 2

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 2
---
 of our common stock issuable upon the exercise of warrants. We will not receive any proceeds from the sale of shares being sold by the selling stockholders. We will, however, receive proceeds on the exercise by the selling stockholders of outstanding warrants for shares of our common stock covered by this prospectus if the warrants are exercised for cash.

We have agreed to bear all of the expenses incurred in connection with the registration of these shares. The selling stockholders will pay or assume brokerage commissions and similar charges, if any, incurred for the sale of the shares. The selling stockholders identified in this prospectus may offer the shares from time to time through public or private transactions at fixed prices, at prevailing market prices, at varying prices determined at the time of sale, or at privately negotiated prices. We provide more information about how the selling stockholders may sell their shares of common stock in the section titled “Plan of Distribution” beginning on page 145 of this prospectus.

Our common stock is listed on the NASDAQ Capital Market (“NASDAQ”) under the symbol “HURA.” The last reported sale price of the common stock on August 11, 2025 was $3.05 per share.

Investing in shares of our common stock involves risks. See “Risk Factors” beginning on page 5 to read about factors you should consider before buying shares of our common stock.

Neither the Securities and Exchange Commission nor any state securities commission or other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

<div align='center'>**The date of this prospectus is , 2025**</div>

TABLE OF CONTENTS

| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS                                  |     | iii |
| PROSPECTUS SUMMARY                                                                    |     |   1 |
| RISK FACTORS                                                                          |     |   5 |
| USE OF PROCEEDS                                                                       |     |  49 |
| DIVIDEND POLICY                                                                       |     |  50 |
| BUSINESS                                                                              |     |  51 |
| MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |     |  99 |
| MANAGEMENT                                                                            |     | 114 |
| EXECUTIVE COMPENSATION                                                                |     | 120 |
| CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS                                  |     | 133 |
| PRINCIPAL STOCKHOLDERS